Rate My Professor Paul Brett

Brett's lab has made significant contributions to the field, including identifying Burkholderia thailandensis as a new species, optimizing polysaccharide purification from pathogenic Burkholderia, developing capsular polysaccharide-based subunit vaccines that provide high-level protection in animal models, and co-developing a rapid, high-accuracy immunoassay licensed by the Thai Food and Drug Administration for 15-minute melioidosis diagnosis. These efforts challenge prior assumptions about subunit vaccine efficacy against B. pseudomallei and advance safe, antigenically defined countermeasures toward human clinical trials. Brett has authored over 125 peer-reviewed publications, cited more than 4,500 times, including 'Layering vaccination with antibiotic therapy results in protection and clearance of a high-dose Burkholderia pseudomallei challenge in Balb/c mice' (2024, Infection and Immunity), 'Development of Melioidosis Subunit Vaccines Using an Adjuvant and Carrier Protein Derived from the Pathogen' (2022, Infection and Immunity), and 'Distinct classes and subclasses of antibodies to hemolysin co-regulated protein 1 (Hcp1) following natural infection or immunization with subunit vaccines against Burkholderia pseudomallei' (2019, Scientific Reports). His cross-continental collaborations with experts in microbiology, immunology, and chemistry enhance global defenses against melioidosis, a disease killing approximately 90,000 people annually.